InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trialsThe company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 millionFollowing the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare…